Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial Meeting Abstract
| Authors: | Faivre-Finn, C.; Vicente, D.; Kurata, T.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J. F.; Spigel, D. R.; Garassino, M. C.; Reck, M.; Senan, S.; Naidoo, J.; Rimner, A.; Wu, Y. L.; Gray, J. E.; Özgüroğlu, M.; Lee, K. H.; Newton, M.; Wang, L.; Thiyagarajah, P.; Antonia, S. J. |
| Abstract Title: | Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S1178 |
| End Page: | S1179 |
| Language: | English |
| ACCESSION: | WOS:000573469102679 |
| DOI: | 10.1016/j.annonc.2020.08.2281 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA49 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work